FSD BIO LABS · Product artwork
A 70 mg research blend of GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg), bringing together components studied in connective-tissue and cellular-response research.
20 vials available
Full prepaid by UPI includes free delivery. COD requires 5% advance and a 1.5% delivery fee. Payment details
See delivery information and return conditions before ordering. Your final total is shown at checkout.
1 laboratory report available
Match the formula to the batch COA. Confirm the exact TB-500 sequence: research on full-length thymosin beta-4 cannot automatically be applied to a shorter fragment.
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
1 report is available for this strength. Match the reported sample and available batch identifiers; contact support if the link to your vial is unclear.
View COA libraryGLOW combines 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 per vial, for a total of 70 mg. GHK-Cu has been studied in collagen and extracellular-matrix biology; BPC-157 in preclinical tendon-cell and tissue-response models. TB-500 is a thymosin-related research material whose exact sequence should be checked against the batch specification. These component research areas explain the scope of the blend without establishing a combined effect.
Match the formula to the batch COA. Confirm the exact TB-500 sequence: research on full-length thymosin beta-4 cannot automatically be applied to a shorter fragment.
These papers concern individual ingredients, not the finished blend. Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
Foundational fibroblast experiments examined collagen synthesis in response to the copper-peptide complex. Laboratory collagen responses do not establish cosmetic or wound-healing outcomes in people.
Read sourceHuman fibroblast cultures and skin samples were used to study collagen responses to GHK-Cu combined with hyaluronic acid. The findings concern that experimental combination, not GHK-Cu alone or an injected product.
Read sourceTendon fibroblast experiments examined growth-hormone receptor expression and responses to growth signals. Cell findings do not demonstrate tendon healing in patients.
Read sourceEndothelial-cell, chick-membrane and rat experiments investigated blood-vessel formation and VEGFR2 signalling. These preclinical models do not establish injury recovery or effectiveness in people.
Read sourceAnalytical work identified an acetylated thymosin beta-4 fragment in material sold as TB-500. This is an identity study, not a clinical efficacy trial of the full-length peptide.
Read sourceResearchers measured the Ac-LKKTETQ fragment and its metabolites in laboratory systems and rats. In the fibroblast assay, significant wound-closure activity was reported for a metabolite, not the parent TB-500. Exact sequence matters.
Read sourceGLOW is currently listed in 70 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
1 laboratory report is published for this compound. Match the selected strength and available batch identifiers, and open the original document to check the actual test scope.
The supplied formula is 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500, totalling 70 mg. Ingredient studies do not establish the finished blend’s results. Check the original report for measured identity and quantities.
A CJC and ipamorelin blend intended for growth hormone signalling research.
An 80 mg research blend of GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg) and KPV (10 mg), combining components studied in tissue biology and inflammatory signalling.
A 10 mg blend of BPC-157 and TB-500 for laboratory research into tissue-related peptide signalling.